PHAT (Phathom Pharmaceuticals) Debt-to-Asset : 0.51 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PHAT Phathom Pharmaceuticals Inc PHAT
35 GF Score
Price $9.50
GF Value $25.54
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Phathom Pharmaceuticals Debt-to-Asset?

Phathom Pharmaceuticals PHAT +4.97% 35 Debt-to-Asset is 0.51 as of Jun. 2026. GuruFocus rates PHAT with a GF Score™ of 35/100 and a GF Value™ of $25.54 (Possible Value Trap). The stock has 2 warning signs investors should review.

Phathom Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.7 Mil. Phathom Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $166.4 Mil. Phathom Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $327.1 Mil. Phathom Pharmaceuticals's debt to asset for the quarter that ended in Jun. 2026 was 0.51.

Phathom Pharmaceuticals  (NAS:PHAT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Phathom Pharmaceuticals Debt-to-Asset Related Terms

Phathom Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Phathom Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phathom Pharmaceuticals Debt-to-Asset Chart

Phathom Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial 0.48 0.59 0.34 0.53 0.82

Phathom Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.87 0.82 0.55 0.51

PHAT vs MNPR, NGNE, AURA: Debt-to-Asset Comparison

For the Biotechnology subindustry, Phathom Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Phathom Pharmaceuticals Debt-to-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Phathom Pharmaceuticals's Debt-to-Asset falls into.


PHAT
35GF Score
Phathom Pharmaceuticals Inc PHAT
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Phathom Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Phathom Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.648 + 211.152) / 259.149
=0.82

Phathom Pharmaceuticals's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.67 + 166.442) / 327.075
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.51 mean?
Phathom Pharmaceuticals (PHAT) has a Debt-to-Asset of 0.51 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Phathom Pharmaceuticals and its competitors.
Is Phathom Pharmaceuticals' Debt-to-Asset too high?
Phathom Pharmaceuticals' current Debt-to-Asset is 0.51. Overall, Phathom Pharmaceuticals has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Phathom Pharmaceuticals' Debt-to-Asset compare to MNPR and NGNE?
Phathom Pharmaceuticals' Debt-to-Asset of 0.51 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Biotechnology company?
A good Debt-to-Asset depends on the Biotechnology industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Phathom Pharmaceuticals and its competitors. Phathom Pharmaceuticals's current Debt-to-Asset is 0.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Phathom Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Phathom Pharmaceuticals (PHAT) is currently considered Possible Value Trap. The stock's GF Value™ is $25.54, compared to a current price of $9.50 — trading 62.8% below its estimated fair value. The current Debt-to-Asset is 0.51. Phathom Pharmaceuticals' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Phathom Pharmaceuticals (PHAT), the current Debt-to-Asset is 0.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Phathom Pharmaceuticals (PHAT) Overvalued in 2026?

Based on GuruFocus' analysis, Phathom Pharmaceuticals stock appears to be undervalued. The current stock price of $9.50 is trading 62.8% below its estimated GF Value™ of $25.54. GuruFocus considers Phathom Pharmaceuticals to be Possible Value Trap.

Key valuation signals for PHAT:

  • Debt-to-Asset: 0.51
  • GF Value™: $25.54 vs. price of $9.50 (62.8% below fair value)
  • GF Score™: 35/100 with 2 warning signs

No single metric tells the full story. See the PHAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Phathom Pharmaceuticals Business Description

Address 100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
35GF Score

Get the complete analysis for PHAT

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.50
Price
$25.54
GF Value